HSIC Stock Rises Amid Expanded Partnership with vVARDIS for Drill-Free Dental Product Curodont

Henry Schein, Inc. HSIC expanded its agreement with vVARDIS, gaining exclusive U.S. distribution rights for Curodont, a drill-free cavity treatment. The partnership is expected to bolster the company's Dental business, with HSIC shares rising 0.1% after the announcement. The company's revenue growth is supported by niche acquisitions and partnerships. Curodont is a proprietary solution that treats early-stage cavities with a drill and needle-free application, with the potential to address up to 80% of untreated cavities in patients. The global dental caries treatment market is predicted to increase from $8.01 billion in 2025 to approximately $12.11 billion by 2034, at a CAGR of 4.70% during 2025-2034.